Patrick E Duffy

List of Publications by Year
in descending order

170 papers	7,050 citations	61945 43 h-index	74108 75 g-index
221 all docs	221 docs citations	221 times ranked	5653 citing authors

#	Article	IF	Citations
1	Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study. Clinical Infectious Diseases, 2022, 74, 1030-1038.	2.9	30
2	Characterization of AMA1â€RON2L complex with native gel electrophoresis and capillary isoelectric focusing. Electrophoresis, 2022, 43, 509-515.	1.3	4
3	Making a good malaria vaccine better. Trends in Parasitology, 2022, 38, 9-10.	1.5	5
4	Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infectious Diseases, The, 2022, 22, 377-389.	4.6	44
5	A single full-length VAR2CSA ectodomain variant purifies broadly neutralizing antibodies against placental malaria isolates. ELife, 2022, 11, .	2.8	13
6	SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. Emerging Infectious Diseases, 2022, 28, 440-444.	2.0	15
7	Effect of three yearsâ€™ seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali. Malaria Journal, 2022, 21, 39.	0.8	11
8	Plasmodium falciparum in Aotus nancymaae: A New Model for Placental Malaria. Journal of Infectious Diseases, 2022, 226, 521-527.	1.9	2
9	Plasma biomarkers of hemoglobin loss in Plasmodium falciparumâ€“infected children identified by quantitative proteomics. Blood, 2022, 139, 2361-2376.	0.6	2
10	Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa. Nature Communications, 2022, 13, .	5.8	8
11	Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines. IScience, 2022, 25, 104739.	1.9	4
12	The Virtues and Vices of Pfs230: From Vaccine Concept to Vaccine Candidate. American Journal of Tropical Medicine and Hygiene, 2022, 107, 17-21.	0.6	4
13	Transmission-Blocking Vaccines: From Conceptualization to Realization. American Journal of Tropical Medicine and Hygiene, 2022, , .	0.6	1
14	Effect of 4 years of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali. Malaria Journal, 2021, 20, 23.	0.8	3
15	Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination. Expert Review of Vaccines, 2021, 20, 185-198.	2.0	45
16	Malaria is a cause of iron deficiency in African children. Nature Medicine, 2021, 27, 653-658.	15.2	35
17	Determinants of Malaria Protective Immunity in Mice Immunized with Live Sporozoites during Trimethoprimâ€“Sulfamethoxazole Prophylaxis. American Journal of Tropical Medicine and Hygiene, 2021, 104, 666-670.	0.6	0
18	A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes. Nature Communications, 2021, 12, 1750.	5.8	39

#	Article	IF	Citations
19	A novel fluorescence and DNA combination for versatile, longâ€term marking of mosquitoes. Methods in Ecology and Evolution, 2021, 12, 1008-1016.	2.2	9
20	Fetal Cytokine Balance, Erythropoietin and Thalassemia but Not Placental Malaria Contribute to Fetal Anemia Risk in Tanzania. Frontiers in Immunology, 2021, 12, 624136.	2.2	2
21	IFN-Î»4 is associated with increased risk and earlier occurrence of several common infections in African children. Genes and Immunity, 2021, 22, 44-55.	2.2	8
22	Pfs230 yields higher malaria transmissionâ€“blocking vaccine activity than Pfs25 in humans but not mice. Journal of Clinical Investigation, 2021, 131, .	3.9	49
23	Malaria Infection Is Common and Associated With Perinatal Mortality and Preterm Delivery Despite Widespread Use of Chemoprevention in Mali: An Observational Study 2010 to 2014. Clinical Infectious Diseases, 2021, 73, 1355-1361.	2.9	18
24	Antibody Levels to Plasmodium falciparum Erythrocyte Membrane Protein 1-DBLÎ³11 and DBLÎ´-1 Predict Reduction in Parasite Density. MSystems, 2021, 6, e0034721.	1.7	3
25	Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature, 2021, 595, 289-294.	13.7	68
26	PlasmodiumPreerythrocytic Vaccine Antigens Enhance Sterile Protection in Mice Induced by Circumsporozoite Protein. Infection and Immunity, 2021, 89, e0016521.	1.0	6
27	A newly characterized malaria antigen on erythrocyte and merozoite surfaces induces parasite inhibitory antibodies. Journal of Experimental Medicine, 2021, 218, .	4.2	2
28	Material strategies and considerations for serologic testing of global infectious diseases. MRS Bulletin, 2021, , 1-5.	1.7	3
29	Can complement fix placental malaria?. BMC Medicine, 2021, 19, 231.	2.3	0
30	Structural basis for placental malaria mediated by Plasmodium falciparum VAR2CSA. Nature Microbiology, 2021, 6, 380-391.	5.9	47
31	An invariant protein that co-localizes with VAR2CSA on Plasmodium falciparum-infected red cells binds to chondroitin sulfate A. Journal of Infectious Diseases, 2021, , .	1.9	3
32	Severe Acute Respiratory Syndrome Coronavirus 2 Seroassay Performance and Optimization in a Population With High Background Reactivity in Mali. Journal of Infectious Diseases, 2021, 224, 2001-2009.	1.9	34
33	Allelic variants of full-length VAR2CSA, the placental malaria vaccine candidate, differ in antigenicity and receptor binding affinity. Communications Biology, 2021, 4, 1309.	2.0	11
34	Assessing and Minimizing the Effect of Malaria on SARS-CoV-2 Serodiagnostics. Frontiers in Tropical Diseases, 2021, 2, .	0.5	7
35	B cell clonal expansion and mutation in the immunoglobulin heavy chain variable domain in response to Pfs230 and Pfs25 malaria vaccines. International Journal for Parasitology, 2021, , .	1.3	3
36	Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques. Npj Vaccines, 2021, 6, 148.	2.9	14

#	Article	IF	Citations
37	PfSPZ Vaccine learns a lesson. Med, 2021, 2, 1289-1291.	2.2	0
38	Effect of Seasonal Malaria Chemoprevention on Immune Markers of Exhaustion and Regulation. Journal of Infectious Diseases, 2020, 221, 138-145.	1.9	3
39	Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults. Clinical Infectious Diseases, 2020, 71, 1481-1490.	2.9	9
40	Unwanted Feedback: Malaria Antibodies Hinder Vaccine Boosting. Cell Host and Microbe, 2020, 28, 504-506.	5.1	1
41	Antibody Therapy Goes to Insects: Monoclonal Antibodies Can Block Plasmodium Transmission to Mosquitoes. Trends in Parasitology, 2020, 36, 880-883.	1.5	6
42	CXCR4 and MIF are required for neutrophil extracellular trap release triggered by Plasmodium-infected erythrocytes. PLoS Pathogens, 2020, 16, e1008230.	2.1	35
43	Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins. Communications Biology, 2020, 3, 395.	2.0	37
44	Ultra-sensitive RDT performance and antigen dynamics in a high-transmission Plasmodium falciparum setting in Mali. Malaria Journal, 2020, 19, 323.	0.8	10
45	Malaria vaccines since 2000: progress, priorities, products. Npj Vaccines, 2020, 5, 48.	2.9	154
46	Adverse pregnancy outcomes among women presenting at antenatal clinics in OuÃ©lessÃ©bougou, Mali. Reproductive Health, 2020, 17, 39.	1.2	7
47	Impact of seasonal malaria chemoprevention on hospital admissions and mortality in children under 5Âyears of age in Ouelessebougou, Mali. Malaria Journal, 2020, 19, 103.	0.8	20
48	Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230. Vaccine, 2020, 38, 5480-5489.	1.7	15
49	Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria. Nature, 2020, 582, 104-108.	13.7	59
50	Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing. JCI Insight, 2020, 5, .	2.3	12
51	Dynamics and Outcomes of Plasmodium Infections in Grammomys surdaster (Grammomys dolichurus) Thicket Rats versus Inbred Mice. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1893-1901.	0.6	2
52	Impact of maternally derived antibodies to Plasmodium falciparum Schizont Egress Antigen-1 on the endogenous production of anti-PfSEA-1 in offspring. Vaccine, 2019, 37, 5044-5050.	1.7	3
53	â€œSpatial heterogeneity of environmental risk in randomized prevention trials: consequences and modelingâ€. BMC Medical Research Methodology, 2019, 19, 149.	1.4	2
54	Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230. Npj Vaccines, 2019, 4, 24.	2.9	35

#	Article	IF	Citations
55	Integrating Scientific English into Biological Sciences PhD Programs in Developing Countries: Strategies from Trainees and Mentor. Education Research International, 2019, 2019, 1-6.	0.6	1
56	Structure Solves the Problem with Malaria Merozoite Vaccines. Trends in Parasitology, 2019, 35, 855-857.	1.5	1
57	Immunity to Severe Malaria: PfEMP1 Tags Tell a Tale. Cell Host and Microbe, 2019, 26, 571-573.	5.1	0
58	Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1. Frontiers in Immunology, 2019, 10, 2295.	2.2	6
59	Proteomics Pipeline for Identifying Variant Proteins in Plasmodium falciparum Parasites Isolated from Children Presenting with Malaria. Journal of Proteome Research, 2019, 18, 3831-3839.	1.8	5
60	Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/AlhydrogelÂ® in mice. Vaccine, 2019, 37, 1038-1045.	1.7	8
61	Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction. Trends in Parasitology, 2019, 35, 483-486.	1.5	31
62	Longitudinal analysis of gamma delta T cell subsets during malaria infections in Malian adults. Malaria Journal, 2019, 18, 69.	0.8	4
63	Functional Antibodies against Placental Malaria Parasites Are Variant Dependent and Differ by Geographic Region. Infection and Immunity, 2019, 87, .	1.0	16
64	Age-dependent increase in antibodies that inhibit Plasmodium falciparum adhesion to a subset of endothelial receptors. Malaria Journal, 2019, 18, 128.	0.8	6
65	A primate model of severe malarial anaemia: a comparative pathogenesis study. Scientific Reports, 2019, 9, 18965.	1.6	5
66	Placental malaria vaccine candidate antigen VAR2CSA displays atypical domain architecture in some Plasmodium falciparum strains. Communications Biology, 2019, 2, 457.	2.0	26
67	Maternally-derived Antibodies to Schizont Egress Antigen-1 and Protection of Infants From Severe Malaria. Clinical Infectious Diseases, 2019, 68, 1718-1724.	2.9	16
68	Malaria vaccine trials in pregnant women: An imperative without precedent. Vaccine, 2019, 37, 763-770.	1.7	22
69	Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A. Vaccine, 2019, 37, 5762-5769.	1.7	13
70	Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1466-1476.	0.6	41
71	Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever. Vaccine, 2018, 36, 2978-2984.	1.7	7
72	Antibody levels to recombinant VAR2CSA domains vary with Plasmodium falciparum parasitaemia, gestational age, and gravidity, but do not predict pregnancy outcomes. Malaria Journal, 2018, 17, 106.	0.8	24

#	Article	IF	Citations
73	NK cells inhibit Plasmodium falciparum growth in red blood cells via antibody-dependent cellular cytotoxicity. ELife, 2018, 7, .	2.8	92
74	Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults. Lancet Infectious Diseases, The, 2018, 18, 969-982.	4.6	101
75	Antibodies to PfsEGXP, an Early Gametocyte-Enriched Phosphoprotein, Predict Decreased Plasmodium falciparum Gametocyte Density in Humans. Journal of Infectious Diseases, 2018, 218, 1792-1801.	1.9	7
76	The Effect of Plasmodium on the Outcome of Ebola Virus Infection in a Mouse Model. Journal of Infectious Diseases, 2018, 218, S434-S437.	1.9	3
77	Optimal mode for delivery of seasonal malaria chemoprevention in Ouelessebougou, Mali: A cluster randomized trial. PLoS ONE, 2018, 13, e0193296.	1.1	23
78	TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight, 2018, 3, .	2.3	59
79	Seroepidemiology of helminths and the association with severe malaria among infants and young children in Tanzania. PLoS Neglected Tropical Diseases, 2018, 12, e0006345.	1.3	7
80	Response to Comment on â€œÎ³Î´ T Cells Are Required for the Induction of Sterile Immunity during Irradiated Sporozoite Vaccinationsâ€• Journal of Immunology, 2018, 200, 1533-1534.	0.4	4
81	Prevalence of Asymptomatic Parasitemia and Gametocytemia in HIV-Infected Children on Differing Antiretroviral Therapy. American Journal of Tropical Medicine and Hygiene, 2018, 98, 67-70.	0.6	2
82	Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Scientific Reports, 2017, 7, 40312.	1.6	54
83	Grammomys surdaster , the Natural Host for Plasmodium berghei Parasites, as a Model to Study Whole-Organism Vaccines against Malaria. American Journal of Tropical Medicine and Hygiene, 2017, 96, 16-0745.	0.6	8
84	Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infectious Diseases, The, 2017, 17, 498-509.	4.6	258
85	Malaria during Pregnancy. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a025551.	2.9	125
86	Antibody-independent mechanisms regulate the establishment of chronic Plasmodium infection. Nature Microbiology, 2017, 2, 16276.	5.9	50
87	Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1. Vaccine Journal, 2017, 24, .	3.2	14
88	A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. Npj Vaccines, 2017, 2, .	2.9	52
89	Maternal Microchimerism Predicts Increased Infection but Decreased Disease due to Plasmodium falciparum During Early Childhood. Journal of Infectious Diseases, 2017, 215, 1445-1451.	1.9	29
90	Host factors that modify Plasmodium falciparum adhesion to endothelial receptors. Scientific Reports, 2017, 7, 13872.	1.6	24

#	Article	IF	Citations
91	Hemoglobin variants shape the distribution of malaria parasites in human populations and their transmission potential. Scientific Reports, 2017, 7, 14267.	1.6	25
92	Î³Î´ T Cells Are Required for the Induction of Sterile Immunity during Irradiated Sporozoite Vaccinations. Journal of Immunology, 2017, 199, 3781-3788.	0.4	80
93	Role of Activins in Hepcidin Regulation during Malaria. Infection and Immunity, 2017, 85, .	1.0	20
94	Systemic Inflammatory Response to Malaria During Pregnancy Is Associated With Pregnancy Loss and Preterm Delivery. Clinical Infectious Diseases, 2017, 65, 1729-1735.	2.9	43
95	Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium. Npj Vaccines, 2017, 2, 34.	2.9	68
96	Trimethoprim-Sulfamethoxazole Prophylaxis During Live Malaria Sporozoite Immunization Induces Long-Lived, Homologous, and Heterologous Protective Immunity Against Sporozoite Challenge. Journal of Infectious Diseases, 2017, 215, 122-130.	1.9	9
97	Malaria in pregnancy: the relevance of animal models for vaccine development. Lab Animal, 2017, 46, 388-398.	0.2	18
98	ATP-degrading ENPP1 is required for survival (or persistence) of long-lived plasma cells. Scientific Reports, 2017, 7, 17867.	1.6	23
99	Effect of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali. Malaria Journal, 2017, 16, 289.	0.8	12
100	Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with AlhydrogelÂ®. Vaccine, 2017, 35, 3232-3238.	1.7	2
101	Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity. PLoS ONE, 2017, 12, e0190312.	1.1	37
102	Malaria Infection and Gametocyte Carriage Rates in Preparation for Transmission Blocking Vaccine Trials in Bancoumana, Mali. American Journal of Tropical Medicine and Hygiene, 2017, 97, 183-187.	0.6	3
103	A Malaria-Resistant Phenotype with Immunological Correlates in a Tanzanian Birth Cohort Exposed to Intense Malaria Transmission. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1190-1196.	0.6	5
104	Optimizing Direct Membrane and Direct Skin Feeding Assays for Plasmodium falciparum Transmission-Blocking Vaccine Trials in Bancoumana, Mali. American Journal of Tropical Medicine and Hygiene, 2017, 97, 719-725.	0.6	7
105	Heterologous Infection of Pregnant Mice Induces Low Birth Weight and Modifies Offspring Susceptibility to Malaria. PLoS ONE, 2016, 11, e0160120.	1.1	11
106	Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060. PLoS ONE, 2016, 11, e0165140.	1.1	11
107	Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report. Malaria Journal, 2016, 15, 476.	0.8	28
108	VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies toPlasmodium falciparumPlacental Malaria. Journal of Infectious Diseases, 2016, 214, 577-586.	1.9	35

#	Article	IF	Citations
109	Cord Blood Hepcidin: Cross-Sectional Correlates and Associations with Anemia, Malaria, and Mortality in a Tanzanian Birth Cohort Study. American Journal of Tropical Medicine and Hygiene, 2016, 95, 817-826.	0.6	10
110	Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230. Journal of Biological Chemistry, 2016, 291, 19913-19922.	1.6	91
111	Utilizing direct skin feeding assays for development of vaccines that interrupt malaria transmission: A systematic review of methods and case study. Vaccine, 2016, 34, 5863-5870.	1.7	20
112	Expanding the antimalarial toolkit: Targeting hostâ€“parasite interactions. Journal of Experimental Medicine, 2016, 213, 143-153.	4.2	22
113	Preparing for future efficacy trials of severe malaria vaccines. Vaccine, 2016, 34, 1865-1867.	1.7	2
114	A Method for Producing Protein Nanoparticles with Applications in Vaccines. PLoS ONE, 2016, 11, e0138761.	1.1	20
115	Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein. PLoS ONE, 2016, 11, e0159449.	1.1	18
116	Safety and Immunogenicity of Pfs25-EPA/AlhydrogelÂ®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria NaÃ¯ve Adults. PLoS ONE, 2016, 11, e0163144.	1.1	114
117	Bacteremia and Malaria in Tanzanian Children Hospitalized for Acute Febrile Illness. Journal of Tropical Pediatrics, 2015, 61, 81-85.	0.7	13
118	Fetal Origins of Malarial Disease: Cord Blood Cytokines as Risk Markers for Pediatric Severe Malarial Anemia. Journal of Infectious Diseases, 2015, 211, 436-444.	1.9	12
119	Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains. Infection and Immunity, 2015, 83, 3771-3780.	1.0	59
120	Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy. Malaria Journal, 2015, 14, 129.	0.8	13
121	Chloroquine neither eliminates liver stage parasites nor delays their development in a murine Chemoprophylaxis Vaccination model. Frontiers in Microbiology, 2015, 6, 283.	1.5	11
122	Designing a VAR2CSA-based vaccine to prevent placental malaria. Vaccine, 2015, 33, 7483-7488.	1.7	71
123	Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine, 2015, 33, 7452-7461.	1.7	152
124	Evaluation of Pregnancy Malaria Vaccine Candidates: The Binding Inhibition Assay. Methods in Molecular Biology, 2015, 1325, 231-239.	0.4	8
125	The march toward malaria vaccines. Vaccine, 2015, 33, D13-D23.	1.7	115
126	The March Toward Malaria Vaccines. American Journal of Preventive Medicine, 2015, 49, S319-S333.	1.6	124

#	Article	IF	Citations
127	High-Throughput Screening Platform Identifies Small Molecules That Prevent Sequestration ofPlasmodium falciparumâ€“Infected Erythrocytes. Journal of Infectious Diseases, 2015, 211, 1134-1143.	1.9	12
128	HIV Treatments Reduce Malaria Liver Stage Burden in a Non-Human Primate Model of Malaria Infection at Clinically Relevant Concentrations In Vivo. PLoS ONE, 2014, 9, e100138.	1.1	12
129	Safety and Comparability of Controlled Human Plasmodium falciparum Infection by Mosquito Bite in Malaria-NaÃ¯ve Subjects at a New Facility for Sporozoite Challenge. PLoS ONE, 2014, 9, e109654.	1.1	21
130	Neither the HIV Protease Inhibitor Lopinavir-Ritonavir nor the Antimicrobial Trimethoprim-Sulfamethoxazole Prevent Malaria Relapse in Plasmodium cynomolgi-Infected Non-Human Primates. PLoS ONE, 2014, 9, e115506.	1.1	6
131	Iron, anemia and hepcidin in malaria. Frontiers in Pharmacology, 2014, 5, 125.	1.6	92
132	Parasite Burden and Severity of Malaria in Tanzanian Children. New England Journal of Medicine, 2014, 370, 1799-1808.	13.9	139
133	Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science, 2014, 344, 871-877.	6.0	117
134	Antibodies to Escherichia coli-Expressed C-Terminal Domains of Plasmodium falciparum Variant Surface Antigen 2-Chondroitin Sulfate A (VAR2CSA) Inhibit Binding of CSA-Adherent Parasites to Placental Tissue. Infection and Immunity, 2013, 81, 1031-1039.	1.0	11
135	Multilaboratory Approach to Preclinical Evaluation of Vaccine Immunogens for Placental Malaria. Infection and Immunity, 2013, 81, 487-495.	1.0	36
136	Identification of VAR2CSA Domain-Specific Inhibitory Antibodies of the Plasmodium falciparum Erythrocyte Membrane Protein 1 Using a Novel Flow Cytometry Assay. Vaccine Journal, 2013, 20, 433-442.	3.2	24
137	Intermittent Preventive Treatment in Pregnant Women Is Associated with Increased Risk of Severe Malaria in Their Offspring. PLoS ONE, 2013, 8, e56183.	1.1	34
138	Cytokine Profiles at Birth Predict Malaria Severity during Infancy. PLoS ONE, 2013, 8, e77214.	1.1	19
139	Iron Deficiency Protects Against Severe Plasmodium falciparum Malaria and Death in Young Children. Clinical Infectious Diseases, 2012, 54, 1137-1144.	2.9	169
140	Pre-erythrocytic malaria vaccines: identifying the targets. Expert Review of Vaccines, 2012, 11, 1261-1280.	2.0	70
141	A Plasma Survey Using 38 PfEMP1 Domains Reveals Frequent Recognition of the Plasmodium falciparum Antigen VAR2CSA among Young Tanzanian Children. PLoS ONE, 2012, 7, e31011.	1.1	35
142	CXC Ligand 9 Response to Malaria during Pregnancy Is Associated with Low-Birth-Weight Deliveries. Infection and Immunity, 2012, 80, 3034-3038.	1.0	35
143	Intermittent Treatment to Prevent Pregnancy Malaria Does Not Confer Benefit in an Area of Widespread Drug Resistance. Clinical Infectious Diseases, 2011, 53, 224-230.	2.9	125
144	NSR-seq transcriptional profiling enables identification of a gene signature of Plasmodium falciparum parasites infecting children. Journal of Clinical Investigation, 2011, 121, 1119-1129.	3.9	72

#	Article	IF	Citations
145	Chondroitin Sulfate A-Adhering Plasmodium falciparum-Infected Erythrocytes Express Functionally Important Antibody Epitopes Shared by Multiple Variants. Journal of Immunology, 2010, 185, 7553-7561.	0.4	56
146	Immunization with VAR2CSA-DBL5 Recombinant Protein Elicits Broadly Cross-Reactive Antibodies to Placental Plasmodium falciparum -Infected Erythrocytes. Infection and Immunity, 2010, 78, 2248-2256.	1.0	34
147	High Throughput Functional Assays of the Variant Antigen PfEMP1 Reveal a Single Domain in the 3D7 Plasmodium falciparum Genome that Binds ICAM1 with High Affinity and Is Targeted by Naturally Acquired Neutralizing Antibodies. PLoS Pathogens, 2009, 5, e1000386.	2.1	63
148	Evidence for Globally Shared, Cross-Reacting Polymorphic Epitopes in the Pregnancy-Associated Malaria Vaccine Candidate VAR2CSA. Infection and Immunity, 2008, 76, 1791-1800.	1.0	47
149	Decreased Susceptibility toPlasmodium falciparumInfection in Pregnant Women with Iron Deficiency. Journal of Infectious Diseases, 2008, 198, 163-166.	1.9	111
150	Fetal Responses during Placental Malaria Modify the Risk of Low Birth Weight. Infection and Immunity, 2008, 76, 1527-1534.	1.0	30
151	Genome-Wide Expression Analysis of Placental Malaria Reveals Features of Lymphoid Neogenesis during Chronic Infection. Journal of Immunology, 2007, 179, 557-565.	0.4	77
152	Six Genes Are Preferentially Transcribed by the Circulating and Sequestered Forms of Plasmodium falciparum Parasites That Infect Pregnant Women. Infection and Immunity, 2007, 75, 4838-4850.	1.0	59
153	Effects of Sex, Parity, and Sequence Variation on Seroreactivity to Candidate Pregnancy Malaria Vaccine Antigens. Journal of Infectious Diseases, 2007, 196, 155-164.	1.9	50
154	Malaria in pregnancy: pathogenesis and immunity. Lancet Infectious Diseases, The, 2007, 7, 105-117.	4.6	458
155	The distinct proteome of placental malaria parasites. Molecular and Biochemical Parasitology, 2007, 155, 57-65.	0.5	56
156	Antibodies to Rhoptryâ€Associated Membrane Antigen Predict Resistance toPlasmodium falciparum. Journal of Infectious Diseases, 2005, 192, 861-869.	1.9	23
157	Maternal Malaria and Gravidity Interact to Modify Infant Susceptibility to Malaria. PLoS Medicine, 2005, 2, e407.	3.9	151
158	Maternal immunization and malaria in pregnancy. Vaccine, 2003, 21, 3358-3361.	1.7	20
159	Plasmodium falciparum adhesion in the placenta. Current Opinion in Microbiology, 2003, 6, 371-376.	2.3	62
160	Malaria Is Related to Decreased Nutritional Status among Male Adolescents and Adults in the Setting of Intense Perennial Transmission. Journal of Infectious Diseases, 2003, 188, 449-457.	1.9	45
161	Antibodies That Inhibit Plasmodium falciparum Adhesion to Chondroitin Sulfate A Are Associated with Increased Birth Weight and the Gestational Age of Newborns. Infection and Immunity, 2003, 71, 6620-6623.	1.0	244
162	Profound Bias in Interferonâ€Î³ and Interleukinâ€6 Allele Frequencies in Western Kenya, Where Severe Malarial Anemia Is Common in Children. Journal of Infectious Diseases, 2002, 186, 1007-1012.	1.9	24

#	Article	IF	Citations
163	Two DBLÎ³ subtypes are commonly expressed by placental isolates of Plasmodium falciparum. Molecular and Biochemical Parasitology, 2002, 122, 201-210.	0.5	44
164	Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends in Parasitology, 2001, 17, 219-223.	1.5	58
165	Human Resistance to Plasmodium falciparum Increases during Puberty and Is Predicted by Dehydroepiandrosterone Sulfate Levels. Infection and Immunity, 2001, 69, 123-128.	1.0	94
166	Interleukin-10 Responses to Liver-Stage Antigen 1 Predict Human Resistance toPlasmodium falciparum. Infection and Immunity, 1999, 67, 3424-3429.	1.0	71
167	Maternal antibodies block malaria. Nature, 1998, 395, 851-852.	13.7	580
168	Maternal malaria and parasite adhesion. Journal of Molecular Medicine, 1998, 76, 162-171.	1.7	100
169	Malaria Transmission-Blocking Vaccines: Present Status and Future Perspectives. , 0, , .		12
170	Natural history of malaria infections during early childhood in twins. Journal of Infectious Diseases, 0, , .	1.9	1